title: Effectiveness of propranolol in the treatment of infantile hemangioma beyond the proliferation phase.
abstract: During the last 5 years, many studies have shown the efficacy of propranolol as first-line treatment for infantile hemangiomas (IHs), but not much has been written about the role of propranolol beyond the proliferation phase of IH (>1 year). Our aim was to assess propranolol efficacy and safety in the treatment of patients older than 1 year. A retrospective study of patients older than 1 year diagnosed with IH and treated in our vascular anomalies clinic between 2009 and 2013 was performed. Eighteen patients older than 1 year with a diagnosis of IH (15 girls, 3 boys) were identified. The mean age at the time of initiation of treatment was 25.7 months (range 13-72 mos). Single lesions were observed in 13 patients and multiple lesions in 5. Fifteen patients had focal lesions and three had segmental. The median duration of treatment with oral propranolol was 11.8 months (range 2-33 mos). Complete response was observed in 72.2% of the patients and partial response in 27.8%. Recurrence was observed in three patients 4.7 months after completion of therapy (range 0.3-8 mos). These patients required further therapy with propranolol for 6 more months. Bradycardia was documented in two patients and night terrors in one patient, which led to discontinuation of treatment. In our experience, propranolol may be useful in the treatment of IHs beyond the proliferation phase (>1 year old), but more studies are needed to support this observation.
authors.affiliation: Department of Pediatric Surgery, Virgen del Rocio Children's Hospital, Sevilla, Spain.
authors.forename: Grecia V
authors.initials: GV
authors.lastname: Vivas-Colmenares
authors.affiliation: Department of Pediatric Dermatology, Virgen del Rocio Children's Hospital, Sevilla, Spain.
authors.forename: Jose
authors.initials: J
authors.lastname: Bernabeu-Wittel
authors.affiliation: Department of Pediatric Surgery, Virgen del Rocio Children's Hospital, Sevilla, Spain.
authors.forename: Veronica
authors.initials: V
authors.lastname: Alonso-Arroyo
authors.affiliation: Department of Pediatric Surgery, Virgen del Rocio Children's Hospital, Sevilla, Spain.
authors.forename: Jose A
authors.initials: JA
authors.lastname: Matute de Cardenas
authors.affiliation: Department of Pediatric Surgery, Virgen del Rocio Children's Hospital, Sevilla, Spain.
authors.forename: Israel
authors.initials: I
authors.lastname: Fernandez-Pineda
mesh_terms: D000284:Administration, Oral; D002648:Child; D002675:Child, Preschool; D005260:Female; D006391:Hemangioma / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D008297:Male; D011433:Propranolol / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D014665:Vasodilator Agents; D011433:Propranolol